Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative Colitis
Status:
Terminated
Trial end date:
2018-03-26
Target enrollment:
Participant gender:
Summary
The main objectives of this study are to evaluate the efficacy, safety, and tolerability of
daily doses of PTG-100 in subjects with moderate to severe ulcerative colitis (UC).
Phase:
Phase 2
Details
Lead Sponsor:
Protagonist Therapeutics Protagonist Therapeutics, Inc.